B.C. First Nation at UN calling for government help in battling toxic drug crisis
NEW YORK – Members of the Tsilhqot'in Nation in British Columbia are at the United Nations headquarters in New York City calling for the provincial and Canadian governments to fund recovery beds and other supports in the battle against the toxic drug crisis.
Chief Roger William with the Tsilhqot'in National Government says they're asking for help to address the crisis in their own way, through culturally centred programming, improving access to treatment and recovery services, and expanding supportive housing.
William says the basic needs of their members must be met in order to stop their 'people from falling into using drugs.'
The news conference comes one year after the Tsilhqot'in Nation declared a local state of emergency after a spike in deaths from toxic drug poisoning in its six member nations in central B.C.
Chief Francis Laceese says the crisis is a 'continuation' of threats to his people's survival in the form of residential schools and the smallpox epidemic that devastated Indigenous communities in B.C. in the early 1860s.
The Tsilhqot'in National Government said last April when it declared the emergency that toxic drugs, combined with the historical and ongoing harms of colonialism, were contributing to higher rates of overdose deaths among Indigenous Peoples.
During Elections
Get campaign news, insight, analysis and commentary delivered to your inbox during Canada's 2025 election.
The statement called on 'all ministries and agencies to work together to end this loss of lives' and pointed to a lack of treatment facilities.
This report by The Canadian Press was first published April 24, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
10 hours ago
- Cision Canada
Protecting Canada's livestock industry with a new vaccine bank Français
OTTAWA ON, /CNW/ - Canada is making significant progress towards the creation of a dedicated foot-and-mouth disease (FMD) vaccine bank, which will build on existing protections for the livestock industry and equip producers with another tool to control and eliminate the disease should an outbreak occur. Following a competitive procurement process, Public Services and Procurement Canada, on behalf of the Canadian Food Inspection Agency, awarded contracts to Boehringer Ingelheim Animal Health and Biogénesis Bagó SA to supply multiple types of vaccine products and develop Canada's first FMD vaccine bank. This FMD vaccine bank complements Canada's current access to vaccines through the North American Foot and Mouth Disease Vaccine Bank, ensuring readily available vaccines for Canadian producers. FMD is a highly contagious and severe disease that affects cattle, sheep, swine, and other cloven-hoofed animals. An FMD infection can cause painful blisters that make it hard for animals to eat, walk, and produce milk, leaving them weak and sick. Preparedness efforts, including building a Canadian FMD vaccine bank, are key to protecting Canadian animals and agriculture. Having a ready supply of FMD emergency vaccines will strengthen our ability to respond effectively to an outbreak should one occur. It could also reduce the number of cases and the duration of the outbreaks. Collaboration between Canada's federal, provincial and territorial governments along with stakeholders plays a key role in Canada's FMD prevention and preparedness plans. These efforts, combined with Canada's existing strict import requirements, on-farm biosecurity measures, and disease surveillance, continue to protect the health of Canadian animals and the economic prosperity of our producers and farming communities. Quotes "Today's announcement highlights our continued commitment to enhancing Canada's animal disease preparedness and prevention plans. Securing our own supply of FMD emergency vaccines will not only help reduce the spread during a potential outbreak but also help protect the livelihood of Canadian farmers by minimizing the impact on international trade." -Paul MacKinnon, President, Canadian Food Inspection Agency "Establishing a dedicated FMD vaccine bank is a vital tool in safeguarding the health of our livestock, market access and the future of our industry. CFIA's announcement marks a key milestone towards our shared goal of strengthening Canada's preparedness against the threat of foot-and-mouth disease. We will continue to work with governments and stakeholders to ensure Canada has a robust emergency preparedness and prevention strategy against FMD." -Tyler Fulton, President, Canadian Cattle Association "The FMD vaccine bank is an important investment in protecting Canadian livestock and livestock producers from this disease. The federal government's support is further proof the cooperative relationship between government and industry in Canada works for producers and processors from coast to coast. We look forward to continuing this partnership on other challenges together." - René Roy, Chair, Canadian Pork Council "Today's announcement is a welcome and pivotal step towards enhancing existing industry defenses, offering producers another critical tool to minimize the impact and return Canada back to 'FMD-free' status in the event of an outbreak. This is vital for protecting animal health and farm sustainability, contributing to a safe, reliable, and consistent food supply for Canadians." -David Wiens, President, Dairy Farmers of Canada Quick Facts Budget 2023 committed $57.5 million over five years, with $5.6 million ongoing, to the CFIA to establish an FMD vaccine bank for Canada, and to further develop FMD response plans. FMD is considered one of the greatest economic threats to Canadian animal agriculture and the economic impacts in Canada are estimated to between $22B and $75B (in 2025 CAD) depending on the mode of introduction and extent of spread. Canada has been free from FMD since 1952, and strict measures are in place to prevent the disease from entering Canada. FMD is not a public health risk and is not considered a food safety issue. Public Services and Procurement Canada led an open, fair and transparent competitive procurement process to establish the contract for the FMD vaccine bank. Information about the solicitation is available on CanadaBuys. Each day, hard-working CFIA employees—including inspectors, veterinarians and scientists—inspect food for safety risks, protect plants from pests and invasive species, and respond to animal diseases that could threaten Canada's national herd and human health. Guided by science-based decision-making and modern regulations, the Agency works tirelessly to ensure access to safe and healthy food in Canada, and support access to international markets for our high-quality agricultural products. To learn more, visit
14 hours ago
This Palestinian boy lost his eye to an unexploded bomb. Thousands of tonnes of explosives may remain in Gaza
Mohamed Hijazi squirms as his father unwraps a bandage for him. He cries and kicks his feet, but his dad manages to eventually place the bandage over his eye. It's nothing, Abu Mohamed tells his child, in a last-ditch effort to calm him down. But the boy is inconsolable. The seven-year-old was playing outside the family home in April with his cousins in Jabalia in northern Gaza, where his family was sheltering, when the children came across a bomb that hadn't detonated. It exploded in front of him, Abu Mohamed said. We went down and found [him] full of blood. The child was rushed to a nearby hospital to be treated for his injuries and then transferred to a hospital in central Gaza with an ophthalmology department that could perform the surgery he needed. His right eye was removed. He may yet lose the left, too, his father said. Children drawn to shiny objects There is no shortage of dangers in Gaza for kids like Mohamed, from airstrikes to disease and malnutrition to the shootings that have become a regular occurrence at aid distribution sites. But the risks posed by the unexploded bombs, mines, booby traps and other munitions that are left lying all around Gaza are particularly insidious. They're different; they're literally shiny, said Luke Irving, chief of the UN's mine action programme in the occupied territories. A child would be immediately drawn to that. WATCH | Mohamed Hijazi's father changes the bandages over his eyes: Début du widget Widget. Passer le widget ? Fin du widget Widget. Retourner au début du widget ? Seven-year-old loses eyesight from unexploded bomb in Gaza Mohamed Hijazi was playing with his cousins near an unexploded bomb in Jabalia when a blast cost him his eyesight. According to the Hamas-run government media office in Gaza, there could be as much as 6,800 tonnes of unexploded ordnance scattered throughout Gaza (new window) . That's based on United Nations estimates that about five to 10 per cent (new window) of all weapons fired into the territory failed to detonate. Irving said there have been 222 confirmed accidents related to unexploded ordnance since Israel began bombing Gaza in the wake of the Oct. 7, 2023, Hamas-led attack that killed some 1,200 people and saw another 250 taken hostage. There have likely been hundreds more such encounters, but such incidents are not always officially counted, said Irving. With much of the medical infrastructure in ruins, doctors in Gaza are preoccupied with trying to stabilize patients rather than assessing the cause of their injuries or deaths, he said. Encounters with unexploded munitions are not always fatal but can leave people with catastrophic injuries and lifelong disabilities that are challenging to manage in a war zone with a decimated health-care system. Just 17 of Gaza's 36 hospitals (new window) were considered partially functional, and over 1,000 health-care workers had been killed as of December 2024, according to Doctors Without Borders. 'Ticking time bombs' In Mohamed's case, doctors told him his left eye might be able to be saved, but he would have to be medically evacuated out of Gaza for the surgery. Until then, his father holds his hand and guides his every step, getting him used to having to relearn simple movements and tasks that he previously did without thinking. As a father, it's very difficult to see Hamood [potentially] losing both his eyes and not living his normal life, said Abu Mohamed, using his son's nickname. I see his cousins playing, and Hamood won't play with them. It's very difficult for me. Operations to clear unexploded ordnance typically can't get underway until a war ends so in Gaza, as fighting between Hamas and Israel continues and shifts to different parts of the enclave and people are repeatedly displaced and return to heavily bombed areas, the munitions remain a persistent danger. And they are not easy to spot. The war has not only claimed the lives of an estimated 54,000 Palestinians; it has left roughly 70 per cent (new window) of the enclave's structures destroyed or damaged, according to the United Nations Office for the Coordination of Humanitarian Affairs. Mixed in with that rubble are hundreds of ticking time bombs, said Irving. Abu Mohamed says his son needs constant attention since his injury. He guides him around to make sure the little boy doesn't stumble. (Mohamed El Saife/CBC News) Photo: (Mohamed El Saife/CBC News) Because it's been fired and its effective release mechanism is ready to explode, it's designed to either hit something, or there's a timer, and it will detonate, he said. They're not designed to sit there, unexploded, and that's the risk. The UN Mine Action Service estimated last year that it could take 14 years to clear Gaza of UXO (new window) . 'No dreams left' Before the war, Mohamed was in kindergarten, at the top of his class, his father said. He held up a photo of the child taken eight or nine months before the accident. At the time, the family had been displaced to southern Gaza because of fighting in the north. Mohamed is dressed in a black tracksuit and stands in front of the tent he and his family were sheltering in. He smiles big for the camera, a sparkle in his eyes. When CBC met him, he was sitting in their home, which had been partially destroyed in the war. He had visible wounds from the explosion. His elbow was wrapped in gauze; his remaining eye welled with tears. The little boy needs emergency evacuation for treatment for his remaining eye because doctors in Gaza don't have the capacity to save it. (Mohamed El Saife/CBC News) Photo: (Mohamed El Saife/CBC News) Mohamed had always wanted to study engineering, his father said. At first, the accident only further motivated him; he told his father that when he recovered, he'd become an engineer so he could help rebuild Gaza. But the prospect of permanently losing his vision has weakened that resolve. This explosion destroyed Hamood's dreams, his father said. And now, because he lost one eye and may lose the other, there are no dreams left. Yasmine Hassan (new window) · CBC News
Cision Canada
16 hours ago
- Cision Canada
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 Français
For over two decades, NOYCIA has fueled emerging research in Canada, driving scientific knowledge in cancer MONTREAL, June 10, 2025 /CNW/ - Novartis Canada is pleased to announce the winners of the 2025 Novartis Oncology Young Canadian Investigator Awards (NOYCIA), an annual national competition dedicated to advancing oncology through the promotion of research by supporting Canadian oncology researchers. This year marks the 22nd year of the awards, which took place on Sunday, June 1st at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. NOYCIA celebrates the innovative work by selecting ten oncology researchers from Canada who have had their abstracts accepted at ASCO and demonstrate excellence in their area of study. "At Novartis, we are deeply committed to advancing scientific knowledge through innovation and collaboration," said Sophia Kajla, Chief Scientific Officer and Vice-President, Scientific Affairs, Novartis Canada. "The NOYCIA Awards remain at the forefront of supporting innovative cancer research in Canada, reflecting Novartis Canada's ongoing commitment to advancing science and improving patient outcomes. We are proud to continue celebrating and investing in early-career oncology leaders who are pushing the boundaries of discovery and clinical impact." Following deliberation by NOYCIA's Scientific Panel, this year's award recipients were selected for their pioneering research, spanning a range of disciplines, from immune checkpoint inhibitors and immunotherapy to healthcare systems and health human resource planning: The 2025 NOYCIA recipients are: Immune Checkpoint Inhibitors and Immunotherapy: Luciana Siqueira, Princess Margaret Cancer Centre Abstract: The association between emotional distress prior to receiving immune checkpoint inhibitors and overall survival among patients with cancer: A population-based study Supervisors: Dr. Lawson Eng & Dr. Marcus Butler Edmond Rafie, Research Center of the Centre Hospitalier de l'Université de Montréal Abstract: Dietary compounds and patterns associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC) Supervisor: Dr. Arielle Elkrief Patrick Tuan Hoang, University of Toronto Abstract: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay Supervisor: Dr. Adrian Sacher Gregoire Marret, University Health Network Abstract: Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC) Supervisor: Dr. Lilian Siu Rami Habib, McGill University Abstract: JAK inhibitor for the treatment of steroid refractory and life threatening immune-related adverse events secondary to immune checkpoint inhibitors Supervisor: Dr. Khashayar Esfahani Transcriptomics and Molecular Analysis: Xin Wang, Princess Margaret Cancer Centre Abstract: Correlative and spatial transcriptomic analysis of olaparib and durvalumab in patients with recurrent/refractory IDH-mutant gliomas Supervisor: Dr. Eric Chen Ronan McLaughlin, Princess Margaret Cancer Centre Abstract: NeoPancONE: GATA6 Expression as a Predictor of benefit to Peri-Operative Modified FOLFIRINOX in Resectable Pancreatic Adenocarcinoma (r-PDAC): A Multicentre Phase II study Supervisor: Dr. Jennifer Knox Patient Experience and Decision-Making: Rena Seeger, University of Ottawa Abstract: Exploring decisional needs of patients considering first line treatment of Advanced EGFR+ lung cancer: An interpretive descriptive study Supervisor: Dr. Paul Wheatley-Price Novel Therapeutic Approaches: Asli Munzur, University of British Columbia Abstract: Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: an exploratory post-hoc analysis of a randomized phase II trial (TheraP ANZUP 1603) Supervisor: Dr. Alex Wyatt Healthcare Systems and Workforce Planning: Philip Ding, University of Alberta Abstract: Rethinking future workforce planning by developing novel metrics of complexity in cancer care Supervisor: Dr. Winson Cheung "For over two decades, NOYCIA has been outstanding in encouraging and promoting Canadian-based cancer research, moving scientific knowledge and understanding in oncology forward through the endorsement of research," said Dr. Paul Wheatley-Price, NOYCIA Chair and medical oncologist, The Ottawa Hospital. "The calibre of research occurring in Canada is truly world-class, and the NOYCIA Awards provides the platform to recognize the tremendous contributions of our emerging leaders. It's incredibly rewarding to be part of this initiative and a privilege to continue to serve as the Chair of the Scientific Panel." In addition to recognizing the achievement and potential of scientific investigation, Dr. David Addiss, 2025 NOYCIA guest speaker and Director, Focus Area for Compassion and Ethics (FACE), Task Force for Global Health, encouraged the award recipients and other attendees to cultivate compassion, which is fundamental to the unique relationship between patients and their healthcare providers. "As clinicians and oncology researchers, you are motivated and sustained by compassion—the desire to alleviate and prevent suffering—which arises from a sense of shared humanity," said Dr. Addiss. "And although science shows that compassionate health care provides significant benefits for patients, providers and health systems, we face growing challenges of resource scarcity, time pressures, and other systemic constraints, which may limit our ability to fully realize this ideal in practice. Despite these challenges, connecting with and nurturing our compassionate impulse on a daily basis allows us to accompany and support our patients in a way that enhances both patient satisfaction and professional fulfillment." Mentorship Matters Program NOYCIA 2025 includes the Mentorship Matters Program which offers mentorship opportunities to trainees who attend the NOYCIA awards dinner. The program provides trainees with the opportunity to network with leaders in Canadian cancer centres. Canadian oncologists co-host a table during the NOYCIA awards allowing trainees from across Canada to have the opportunity to hear from mentors about career paths, programs and opportunities that their centres provide and to ask questions. About the Novartis Oncology Young Investigators Award (NOYCIA) With a mission to support Canadian oncology researchers, NOYCIA provides funding, support, and recognition to 10 researchers that demonstrate excellence in their specialist field of study. Eligible applicants include Post-Doctoral Students, Residents, Fellows, Graduate Students, Medical Students, PhD Candidates and Undergraduates who are affiliated with a Canadian institution and are the first author of an abstract accepted for the annual ASCO meeting. For more information about NOYCIA, go to: About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit
